Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Positive aspects include a 42% growth in Passenger segment revenue, improved adjusted EBITDA, and a share repurchase program. However, concerns arise from flat Medical revenue, maintenance downtime affecting margins, and competitive pressures. The Q&A reveals strategic initiatives but lacks clarity on repositioning impacts and new routes. The strategic partnership with Skyports and OrganOx, along with strong Passenger segment performance, offset some negatives, but uncertainties in the Medical segment and operational challenges lead to a neutral sentiment.
Revenue Growth Revenue growth of 11% year-over-year, excluding Canada, driven by strong performance in the Passenger segment.
Passenger Segment Revenue Growth Passenger segment revenue grew 42% year-over-year, excluding Canada, attributed to durable competitive positioning and actions taken to improve profitability.
Adjusted EBITDA Improvement Adjusted EBITDA improved by $2.3 million year-over-year, with Passenger segment adjusted EBITDA improving by $2.7 million, marking the first profitable quarter since going public.
Medical Revenue Medical revenue remained flat year-over-year at $35.9 million, with variability in monthly growth trends impacting results.
Medical Segment Adjusted EBITDA Margin Medical segment adjusted EBITDA margin fell 80 basis points year-over-year to 11.4%, primarily due to elevated scheduled maintenance downtime.
Capital Expenditures Capital expenditures were $3.2 million in the quarter, driven by capitalized aircraft maintenance and aircraft acquisition payments.
Cash and Short-term Investments Ended the quarter with $120 million in cash and short-term investments, providing flexibility for strategic investments.
Corporate Expenses Unallocated corporate expenses rose just 1.6% year-over-year, indicating a focus on cost efficiencies.
Flight Margin Improvement Achieved an 840 basis point improvement in flight margin, contributing to significant profitability improvement in the Passenger segment.
SG&A Reduction Passenger segment adjusted SG&A reduced by 16%, contributing to overall profitability improvement.
New Medical Customers: Successfully launched service with two new large hospitals on April 1st, contributing to an all-time record for trip volumes in April.
Passenger Segment Revenue Growth: Passenger segment revenue grew 42% year-over-year, excluding Canada.
European Market Performance: Strong revenue growth and significantly improved profitability in Europe following restructuring.
Operational Efficiency Improvements: Achieved the Passenger segment's first adjusted EBITDA profitable first quarter since going public, driven by cost rationalization initiatives.
Aircraft Maintenance Downtime: Elevated scheduled maintenance downtime impacted Medical segment profitability, but expected to improve in the second half of 2025.
Exit from Canada: Exited the Canadian market in August 2024, contributing to improved profitability.
Focus on eVTOL Transition: Positioned well for the transition from helicopters to eVTOL due to scale, brand, and technology.
Economic Uncertainty: The company acknowledges potential impacts of economic uncertainty on the Passenger segment, particularly in light of softening travel fundamentals reported by airlines.
Helicopter Tour Incident: A recent helicopter tour incident may have a transitory impact on demand for Blade's New York area services, with a moderate impact observed in April.
Maintenance Downtime: Elevated scheduled maintenance downtime on the fleet during Q1 2025 negatively affected Medical segment profitability and is expected to continue impacting margins in Q2 2025.
Regulatory Compliance: Blade emphasizes the importance of safety standards and compliance, particularly in light of the helicopter tour incident, which underscores the need for rigorous operator audits and pilot qualifications.
Market Competition: The company faces competitive pressures, particularly in the Medical segment, where they are focused on maintaining a pricing advantage through strategic fleet positioning.
Supply Chain Challenges: The company is managing supply chain challenges related to aircraft maintenance and operational performance, which could affect financial results.
Passenger Segment Revenue Growth: Passenger segment revenue grew 42% year-over-year, excluding Canada.
Medical Business Growth: Medical business launched service with two new large hospitals, contributing to record trip volumes in April.
Cost Rationalization Initiatives: Actions taken to improve profitability include exit from Canada and cost efficiency initiatives.
Aircraft Acquisition Strategy: Completed a rapid period of aircraft acquisitions, now focused on improving operational and financial performance.
Safety Standards: Blade requires operators to maintain higher pilot flight hours than FAA minimums, ensuring safety.
Transition to eVTOL: Passenger segment is well positioned for the transition from helicopters to eVTOL.
Cash Position: Blade ended Q1 with $120 million in cash and short-term investments, ready for strategic investments.
2025 Revenue Guidance: Reiterating revenue and adjusted EBITDA guidance for the year.
Medical Revenue Growth: Expecting double-digit revenue growth for Medical in 2025.
Medical Segment EBITDA Margins: Expecting adjusted EBITDA margins to be approximately 15% for the year.
Passenger Segment Outlook: Expecting ongoing year-over-year benefits from cost and restructuring actions.
Corporate Expenses: Expecting adjusted unallocated corporate expenses to decline slightly year-over-year in 2025.
Free Cash Flow: Expecting to generate positive free cash flow before aircraft acquisitions.
Share Repurchase Program: During the quarter, Blade deployed $4.3 million for share repurchases, resulting in the withholding of approximately $1.5 million shares at an average price of approximately $2.91.
The earnings call summary reveals positive financial performance, particularly in the Passenger segment's margin and EBITDA growth. The Medical segment shows growth potential, despite a slight margin decline. The Q&A highlights strategic capital allocation and a focus on the Medical segment, with no operational impact from divestitures. The sale of the Passenger business simplifies the company’s focus and aligns with growth strategies. Additionally, positive cash position and cost efficiencies further support a positive outlook. However, vague responses in the Q&A introduce some uncertainty, tempering the sentiment to 'Positive' rather than 'Strong positive.'
The earnings call reveals several positive aspects: a strong revenue growth in the passenger segment, improved EPS, and the first adjusted EBITDA profitable quarter. The share repurchase program is a positive signal for shareholders. Despite some challenges like maintenance downtime affecting margins, the company shows resilience and strategic focus, including potential growth in Europe and eVTOL deployment plans. The Q&A session highlights positive analyst sentiment, though some answers lacked clarity. Overall, the strategic initiatives and financial improvements suggest a positive stock price movement.
The earnings call presents a mixed outlook. Positive aspects include a 42% growth in Passenger segment revenue, improved adjusted EBITDA, and a share repurchase program. However, concerns arise from flat Medical revenue, maintenance downtime affecting margins, and competitive pressures. The Q&A reveals strategic initiatives but lacks clarity on repositioning impacts and new routes. The strategic partnership with Skyports and OrganOx, along with strong Passenger segment performance, offset some negatives, but uncertainties in the Medical segment and operational challenges lead to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.